<DOC>
	<DOC>NCT01631097</DOC>
	<brief_summary>This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics, safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of hepatic impairment and normal hepatic function.</brief_summary>
	<brief_title>A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>BMI between 18 to 38 kg/m2 diagnosis of chronic or stable hepatic insufficiency, with a ChildPugh classification scores of mild, moderate or severe. Current or previous history of hepatic carcinoma, hepatorenal syndrome, portacaval shunt surgery, significant hepatic encephalopathy, severe ascites, or pleural effusion Currently undergoing dialysis Poor peripheral venous access Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>